Arcturus Therapeutics HoldingsARCT -0.58%54 PS Ratio is 4.39 as of Jun. 30, 2026, which is at its 10-year median of 4.39. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 935 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 68.77% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arcturus Therapeutics Holdings's share price is $6.82.
Arcturus Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.56. Hence, Arcturus Therapeutics Holdings's PS Ratio for today is 4.39.
The historical rank and industry rank for Arcturus Therapeutics Holdings's PS Ratio or its related term are showing as below:
ARCT'
s PS Ratio Range Over the Past 10 Years
Min: 0.85 Med: 4.39 Max: 183.02
Current: 4.39
During the past 13 years, Arcturus Therapeutics Holdings's highest PS Ratio was 183.02. The lowest was 0.85. And the median was 4.39.
ARCT's PS Ratio is ranked better than 68.77% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs ARCT: 4.39
During the past 13 years, Arcturus Therapeutics Holdings's highest 3-Year average Revenue per Share Growth Rate was 132.70% per year. The lowest was -51.90% per year. And the median was -25.65% per year.
Back to Basics: PS Ratio
Arcturus Therapeutics Holdings (NAS:ARCT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Arcturus Therapeutics Holdings PS Ratio Related Terms
Arcturus Therapeutics Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's PS Ratio falls into.
Arcturus Therapeutics Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Arcturus Therapeutics Holdings's Share Price of today is $6.82. Arcturus Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.56.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Arcturus Therapeutics Holdings (ARCT) has a PS Ratio of 4.39 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arcturus Therapeutics Holdings and its competitors. This is near median its historical median of 4.39. Over the past decade, Arcturus Therapeutics Holdings' PS Ratio has ranged from 0.85 to 183.02. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #292 out of 935 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Arcturus Therapeutics Holdings' PS Ratio too high?
Arcturus Therapeutics Holdings' current PS Ratio of 4.39 is near median its 10-year median of 4.39. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 183.02. The Biotechnology industry median PS Ratio is 9.37. Arcturus Therapeutics Holdings' value of 4.39 is 53.1% below this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #292 out of 935 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' PS Ratio compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #292 out of 935 companies for PS Ratio. This puts Arcturus Therapeutics Holdings in the upper half of its industry. The industry median PS Ratio is 9.37. Arcturus Therapeutics Holdings' value of 4.39 is 53.1% below this benchmark. Historically, Arcturus Therapeutics Holdings' own PS Ratio has ranged from 0.85 to 183.02 over the past decade. While the company's 10-year median is 4.39 vs. the industry median of 9.37, Arcturus Therapeutics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current PS Ratio of 4.39 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current PS Ratio is 4.39, which is near median its own 10-year median of 4.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.82 — trading 54.6% above its estimated fair value. The current PS Ratio is 4.39, which is near median its 10-year median of 4.39 and 53.1% below the Biotechnology industry median of 9.37. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current PS Ratio is 4.39 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $6.82 is trading 54.6% above its estimated GF Value™ of $4.41.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
PS Ratio: 4.39 (near median its 10-year median of 4.39)
GF Value™: $4.41 vs. price of $6.82 (54.6% above fair value)
Industry Position: 53.1% below the Biotechnology median (#292 of 935)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score
Get the complete analysis for ARCT
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
